Fecal microbiota transplant as a new therapeutic in the management of type 2 Diabetes Mellitus

Introduction Type 2 diabetes mellitus (DM2) is a global public health problem, and is one of the main causes of disability, premature death and complications, resulting from poor glycemic control, poor monitoring and underlying chronic pathologies. The budget for care is increasingly scarce, which is why there is a need to find new cost-effective therapeutic options that offer multiple benefits and contribute to achieving therapeutic objectives.Objective: to determine the efficacy of fecal microbiota transplantation as a new therapy in the management of type 2 diabetes.Results: In the literature review of both human and animal models using FMT, a reduction in blood glucose values, body mass index (BMI), glycosylated hemoglobin (HbA1c), systolic blood pressure, triglycerides and total cholesterol is reported, improving cost-effectiveness in treatment.Conclusion: FTM is an excellent cost-effective alternative or complementary to conventional treatment of type 2 DM; the benefits are significant in terms of therapy and budget reduction in health systems, however, in developing countries its implementation is not feasible.